New fertility drug

Elonva (corifollitropin alfa) is a new sustained follicle stimulant for women participating in assisted reproductive technology programmes.

Corifollitropin alfa is a sustained follicle stimulant with a prolonged duration of FSH activity.

A single subcutaneous injection of Elonva can initiate and sustain multiple follicular growth for a week and may replace the first 7 injections of any daily recombinant FSH preparation in a controlled ovarian stimulation treatment cycle.

View Elonva drug record

Further information: Schering-Plough

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more